Company overview
BPGbio is a clinical-stage biopharmaceutical company using its NAi Interrogative Biology platform, powered by Bayesian causal AI, to discover novel targets from multi-omics data across oncology, rare diseases, and neurology. The company advances a diversified pipeline including BPM31510-IV, a mitochondrial metabolic modulator in Phase 2b for glioblastoma and Phase 2a for pancreatic cancer, targeting tumor metabolism to sensitize to chemotherapy and radiation. Additional programs address squamous cell carcinoma, epidermolysis bullosa, and protein homeostasis via targeted protein degradation.
BPGbio is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include bpgbio, bayesian ai drug discovery, mitochondrial therapeutics, oncology pipeline, nai platform.
Structured facts
- Website
- https://bpgbio.com
- Markets served
- United States & Americas
- Keywords
- bpgbio, bayesian ai drug discovery, mitochondrial therapeutics, oncology pipeline, nai platform
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is BPGbio's core technology platform?
- NAi Interrogative Biology, a biology-first Bayesian causal AI platform that analyzes multi-omics data from over 100,000 patients to identify novel drug targets across oncology, rare diseases, and neurology.
- What are the clinical-stage assets in BPGbio's pipeline?
- Lead candidate BPM31510-IV is in Phase 2b for glioblastoma, completed Phase 2a for pancreatic cancer, and explores indications like Primary CoQ10 Deficiency and squamous cell carcinoma; additional programs include BRG399 for immuno-oncology.
- What partnerships support BPGbio's capabilities?
- Partners include Oak Ridge National Labs for supercomputing, Department of Defense, Sanofi, Harvard Medical School, and Advent Health for AI-driven research in oncology, metabolic diseases, and COVID-19 challenges.
Related editorial coverage
- Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts
- Merck’s Harpoon acquisition deepens oncology pipeline ahead of Keytruda risk
- ALX Oncology to Present at 2026 Jefferies Global Healthcare Conference, Highlighting Oncology Pipeline
- Rallybio Taps Avenzo Therapeutics for Reverse Merger to Advance Oncology Pipeline
- Fierce Biotech Week 2026: AI & Oncology Pipeline Recap
- Pfizer Presents LORBRENA and BRAFTOVI Cancer Trial Updates at ASCO 2026
Explore lab tools and QA/QC resources for R&D teams.
